CollPlant Biotechnologies Ltd. (CLGN)

Market Cap	41.58M
Revenue (ttm)	650,000
Net Income (ttm)	-17.42M
Shares Out	11.45M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,273
Open	3.630
Previous Close	3.600
Day's Range	3.385 - 3.660
52-Week Range	3.240 - 6.750
Beta	0.51
Analysts	Strong Buy
Price Target	12.50 (+244.35%)
Earnings Date	Nov 27, 2024

About CLGN

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: CLGN
• Website: https://www.collplant.com

Financial Performance

In 2023, CollPlant Biotechnologies's revenue was $10.96 million, an increase of 3565.22% compared to the previous year's $299,000. Losses were -$7.02 million, -58.53% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for CLGN stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 244.35% from the latest price.

Price Target

$12.5

(244.35% upside)

Analyst Consensus: Strong Buy